 |
| |
| |
| |
| |
| |
| |
|
| TissGeneSummary for INSL3 |
 Gene summary |
| Basic gene information | Gene symbol | INSL3 |
| Gene name | insulin-like 3 (Leydig cell) | |
| Synonyms | RLF|RLNL|ley-I-L | |
| Cytomap | UCSC genome browser: 19p13.2-p12 | |
| Type of gene | protein-coding | |
| RefGenes | NM_001265587.1, NM_005543.3, | |
| Description | insulin-like 3leydig insulin -like hormoneleydig insulin-like peptideprepro-INSL3relaxin-like factor b | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 146738 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000248099 | ||
| HPRD : 08854 | ||
| Vega : OTTHUMG00000183481 | ||
| Protein | UniProt: go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_INSL3 | |
| BioGPS: 3640 | ||
| Pathway | NCI Pathway Interaction Database: INSL3 | |
| KEGG: INSL3 | ||
| REACTOME: INSL3 | ||
| Pathway Commons: INSL3 | ||
| Context | iHOP: INSL3 | |
| ligand binding site mutation search in PubMed: INSL3 | ||
| UCL Cancer Institute: INSL3 | ||
| Assigned class in TissGDB* | A | |
| Included tissue-specific gene expression resources | HPA,TiGER,GTEx | |
| Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | BrainTestis | |
| Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | GBM,LGGTGCT | |
| Reference showing the relevant tissue of INSL3 | Relaxin gene family in teleosts: phylogeny, syntenic mapping, selective constraint, and expression analysis. Good-Avila SV, Yegorov S, Harron S, Bogerd J, Glen P, Ozon J, Wilson BC. BMC Evol Biol. 2009 Dec 16;9:293. doi: 10.1186/1471-2148-9-293. (pmid:20015397) go to articleSynthesis of fluorescent analogs of relaxin family peptides and their preliminary in vitro and in vivo characterization. Chan LJ, Smith CM, Chua BE, Lin F, Bathgate RA, Separovic F, Gundlach AL, Hossain MA, Wade JD. Front Chem. 2013 Dec 6;1:30. doi: 10.3389/fchem.2013.00030. eCollection 2013. (pmid:24790958) go to article | |
| Description by TissGene annotations | ||
| * Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO term | PubMed ID |
| Top |
| TissGeneExp for INSL3 |
| Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
 |
| Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
 |
| Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| - Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
| Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
| THCA | -0.810730348 | -2.083810009 | 1.273079661 | 2.15E-06 | 7.84E-06 |
| KIRC | -0.934069919 | -2.098343531 | 1.164273611 | 1.53E-10 | 5.29E-10 |
| LUAD | -0.801936251 | -2.196822458 | 1.394886207 | 6.37E-13 | 5.09E-12 |
| STAD | 0.271930775 | -0.777144225 | 1.049075 | 0.000835 | 0.004614042 |
| KIRP | -1.073075475 | -2.269775475 | 1.1967 | 7.20E-05 | 0.000257455 |
| Top |
| TissGene-miRNA for INSL3 |
| Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
| Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
| Top |
| TissGeneMut for INSL3 |
| TissGeneSNV for INSL3 |
| nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
 |
 |
| Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
 |
| - nsSNVs sorted by frequency. |
| AAchange | Cancer type | # samples |
| p.T60A | COAD | 4 |
| p.T60A | PCPG | 3 |
| p.T60A | READ | 3 |
| p.T86M | BRCA | 1 |
| p.D105N | LUAD | 1 |
| p.P113L | SKCM | 1 |
| p.V39G | ACC | 1 |
| p.L94V | BLCA | 1 |
| p.P113S | SKCM | 1 |
| p.T60A | BRCA | 1 |
| p.V39G | READ | 1 |
| p.S149L | CESC | 1 |
| p.E54K | COAD | 1 |
| p.R73X | COAD | 1 |
| p.D105N | SKCM | 1 |
| p.G88* | LUSC | 1 |
| Top |
| TissGeneCNV for INSL3 |
| Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
 |
| Top |
| TissGeneFusions for INSL3 |
| Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
| Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
| Chimerdb3.0 | TopHat-Fusion | UCEC | TCGA-AJ-A3NH-01A | FNBP4-INSL3 | In-Frame | chr11:47752925 | chr19:17927867 |
| Top |
| TissGeneNet for INSL3 |
| Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
| BRCA (tumor) | BRCA (normal) |
| INSL3, RXFP2 (tumor) | INSL3, RXFP2 (normal) |
 |  |
| COAD (tumor) | COAD (normal) |
| INSL3, RXFP2 (tumor) | INSL3, RXFP2 (normal) |
 |  |
| HNSC (tumor) | HNSC (normal) |
| INSL3, RXFP2 (tumor) | INSL3, RXFP2 (normal) |
 |  |
| KICH (tumor) | KICH (normal) |
| INSL3, RXFP2 (tumor) | INSL3, RXFP2 (normal) |
 |  |
| KIRC (tumor) | KIRC (normal) |
| INSL3, RXFP2 (tumor) | INSL3, RXFP2 (normal) |
 |  |
| KIRP (tumor) | KIRP (normal) |
| INSL3, RXFP2 (tumor) | INSL3, RXFP2 (normal) |
 |  |
| LIHC (tumor) | LIHC (normal) |
| INSL3, RXFP2 (tumor) | INSL3, RXFP2 (normal) |
 |  |
| LUAD (tumor) | LUAD (normal) |
| INSL3, RXFP2 (tumor) | INSL3, RXFP2 (normal) |
 |  |
| LUSC (tumor) | LUSC (normal) |
| INSL3, RXFP2 (tumor) | INSL3, RXFP2 (normal) |
 |  |
| PRAD (tumor) | PRAD (normal) |
| INSL3, RXFP2 (tumor) | INSL3, RXFP2 (normal) |
 |  |
| STAD (tumor) | STAD (normal) |
| INSL3, RXFP2 (tumor) | INSL3, RXFP2 (normal) |
 |  |
| THCA (tumor) | THCA (normal) |
| INSL3, RXFP2 (tumor) | INSL3, RXFP2 (normal) |
 |  |
| Top |
| TissGeneProg for INSL3 |
| Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
 |
| Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Top |
| TissGeneClin for INSL3 |
| TissGeneDrug for INSL3 |
| Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
| DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Top |
| TissGeneDisease for INSL3 |
| Disease information associated with TissGene (DisGeNet, 2016-06-01) |
| Disease ID | Disease name | # pubmeds | Source |
| umls:C0010417 | Cryptorchidism | 28 | BeFree,CLINVAR,CTD_human,GAD,MGD,UNIPROT |
| umls:C0431663 | Bilateral Cryptorchidism | 8 | BeFree |
| umls:C0549473 | Thyroid carcinoma | 3 | BeFree |
| umls:C0000768 | Congenital Abnormality | 2 | BeFree |
| umls:C0020619 | Hypogonadism | 2 | BeFree |
| umls:C0022735 | Klinefelter Syndrome | 2 | BeFree,GAD,LHGDN |
| umls:C0432474 | Klinefelter's syndrome - male with more than two X chromosomes | 2 | BeFree |
| umls:C2919755 | Testicular dysgenesis syndrome | 2 | BeFree |
| umls:C0001430 | Adenoma | 1 | BeFree |
| umls:C0001630 | Adrenal Rest Tumor | 1 | BeFree |
| umls:C0010709 | Cyst | 1 | BeFree |
| umls:C0011847 | Diabetes | 1 | BeFree |
| umls:C0011849 | Diabetes Mellitus | 1 | BeFree |
| umls:C0013537 | Eclampsia | 1 | BeFree |
| umls:C0016034 | Breast Fibrocystic Disease | 1 | BeFree |
| umls:C0020507 | Hyperplasia | 1 | LHGDN |
| umls:C0021364 | Male infertility | 1 | BeFree,GAD |
| umls:C0023600 | Leydig cell hyperplasia | 1 | BeFree |
| umls:C0023601 | Leydig Cell Tumor | 1 | BeFree |
| umls:C0024623 | Malignant neoplasm of stomach | 1 | BeFree |
| umls:C0028960 | Oligospermia | 1 | BeFree |
| umls:C0029456 | Osteoporosis | 1 | BeFree,LHGDN |
| umls:C0032002 | Pituitary Diseases | 1 | BeFree |
| umls:C0032460 | Polycystic Ovary Syndrome | 1 | GAD |
| umls:C0040128 | Thyroid Diseases | 1 | LHGDN |
| umls:C0040136 | Thyroid Neoplasm | 1 | LHGDN |
| umls:C0149925 | Small cell carcinoma of lung | 1 | BeFree |
| umls:C0153594 | Malignant neoplasm of testis | 1 | BeFree |
| umls:C0206081 | Hyperandrogenism | 1 | LHGDN |
| umls:C0238462 | Medullary carcinoma of thyroid | 1 | BeFree |
| umls:C0282612 | Prostatic Intraepithelial Neoplasias | 1 | BeFree |
| umls:C0334409 | Leydig cell tumor, benign | 1 | BeFree |
| umls:C0431664 | Unilateral Cryptorchidism | 1 | BeFree |
| umls:C0596263 | Carcinogenesis | 1 | BeFree |
| umls:C0600139 | Prostate carcinoma | 1 | BeFree |
| umls:C0686619 | Secondary malignant neoplasm of lymph node | 1 | BeFree |
| umls:C0699791 | Stomach Carcinoma | 1 | BeFree |
| umls:C0855197 | Testicular malignant germ cell tumor | 1 | BeFree |
| umls:C0919267 | ovarian neoplasm | 1 | LHGDN |
| umls:C1176475 | Ductal Carcinoma | 1 | BeFree |
| umls:C1384583 | Congenital absence of germinal epithelium of testes | 1 | BeFree |
| umls:C1704272 | Benign Prostatic Hyperplasia | 1 | BeFree |
Copyright 2016-Present - The University of Texas Health Science Center at Houston (UTHealth) Web File Viewing | How to Report, Fraud, Waste and Abuse | State of Texas | Statewide Search | Texas Homeland Security | Site Policies |